SG11201503942RA - Egfr and c-met-fibronectin type iii domain binding molecules - Google Patents

Egfr and c-met-fibronectin type iii domain binding molecules

Info

Publication number
SG11201503942RA
SG11201503942RA SG11201503942RA SG11201503942RA SG11201503942RA SG 11201503942R A SG11201503942R A SG 11201503942RA SG 11201503942R A SG11201503942R A SG 11201503942RA SG 11201503942R A SG11201503942R A SG 11201503942RA SG 11201503942R A SG11201503942R A SG 11201503942RA
Authority
SG
Singapore
Prior art keywords
egfr
met
binding molecules
type iii
fibronectin type
Prior art date
Application number
SG11201503942RA
Inventor
Mark Anderson
Ricardo Attar
Michael Diem
Linus Hyun
Steven Jacobs
Alastair King
Donna Klein
Sheri Moores
Karyn O'neil
Kristen Picha
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50776675&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201503942R(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201503942RA publication Critical patent/SG11201503942RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201503942RA 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules SG11201503942RA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201261728914P 2012-11-21 2012-11-21
US201261728912P 2012-11-21 2012-11-21
US201261728906P 2012-11-21 2012-11-21
US201361782550P 2013-03-14 2013-03-14
US201361809541P 2013-04-08 2013-04-08
PCT/US2013/071267 WO2014081944A2 (en) 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules

Publications (1)

Publication Number Publication Date
SG11201503942RA true SG11201503942RA (en) 2015-06-29

Family

ID=50776675

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201707488TA SG10201707488TA (en) 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules
SG11201503942RA SG11201503942RA (en) 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201707488TA SG10201707488TA (en) 2012-11-21 2013-11-21 Egfr and c-met-fibronectin type iii domain binding molecules

Country Status (21)

Country Link
US (4) US9695228B2 (en)
EP (3) EP2922566B1 (en)
JP (3) JP6393270B2 (en)
KR (2) KR102210196B1 (en)
CN (5) CN108546300B (en)
AU (3) AU2013347952B2 (en)
CA (1) CA2891485A1 (en)
CL (1) CL2015001353A1 (en)
EA (2) EA035559B1 (en)
ES (2) ES2696148T3 (en)
HK (1) HK1215680A1 (en)
IL (2) IL238730B (en)
MX (2) MX369334B (en)
MY (1) MY176820A (en)
NI (1) NI201500070A (en)
NZ (1) NZ708349A (en)
PH (1) PH12015501134A1 (en)
SG (2) SG10201707488TA (en)
UA (1) UA118096C2 (en)
WO (1) WO2014081944A2 (en)
ZA (1) ZA201504427B (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2855509T (en) 2012-05-25 2018-08-03 Janssen Biotech Inc Non-natural consensus albumin binding domains
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SI2922872T1 (en) 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecific egfr/c-met antibodies
JP6412503B2 (en) 2012-11-21 2018-10-24 ピーティーシー セラピューティクス， インコーポレイテッド Substituted reverse pyrimidine Bmi-1 inhibitors
SG11201505508TA (en) * 2013-01-25 2015-08-28 Janssen Biotech Inc Kv1.3 antagonists and methods of use
TWI692477B (en) 2013-08-30 2020-05-01 美商Ｐｔｃ治療公司 Substituted pyrimidine bmi-1 inhibitors
CN105899226B (en) 2013-10-14 2020-05-12 詹森生物科技公司 Cysteine engineered fibronectin type III domain binding molecules
EP3071553A4 (en) 2013-11-21 2017-08-02 PTC Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
CN105085489B (en) 2014-11-05 2019-03-01 益方生物科技（上海）有限公司 Pyrimidine or pyridine compounds and their, preparation method and medical usage
CN116832890A (en) * 2015-04-06 2023-10-03 中尺度技术有限责任公司 Method of operating an assay system and ECL immunoassay system
KR20180002782A (en) 2015-05-06 2018-01-08 얀센 바이오테크 인코포레이티드 Prostate specific membrane antigen (PSMA) bispecific binding agents and uses thereof
MA42060A (en) 2015-05-06 2018-03-14 Janssen Biotech Inc TYPE III FIELDS OF FIBRONECTINES BINDING PROSTATE-SPECIFIC MEMBRANARY ANTIGEN
US20170002058A1 (en) * 2015-06-30 2017-01-05 Regents Of The University Of Minnesota Compositions and methods that involve protein scaffolds that specifically bind to hepatocyte growth factor receptor
US10584152B2 (en) * 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102444835B1 (en) 2016-05-26 2022-09-19 리커리엄 아이피 홀딩스, 엘엘씨 EGFR inhibitor compounds
SG11201810687SA (en) * 2016-06-03 2018-12-28 Janssen Biotech Inc Serum albumin-binding fibronectin type iii domains
AU2017281083B2 (en) * 2016-06-21 2022-01-27 Janssen Biotech, Inc. Cysteine engineered fibronectin type III domain binding molecules
TWI782930B (en) 2016-11-16 2022-11-11 美商再生元醫藥公司 Anti-met antibodies, bispecific antigen binding molecules that bind met, and methods of use thereof
US10597438B2 (en) 2016-12-14 2020-03-24 Janssen Biotech, Inc. PD-L1 binding fibronectin type III domains
JP7104703B2 (en) 2016-12-14 2022-07-21 ヤンセン バイオテツク，インコーポレーテツド CD8A-binding fibronectin type III domain
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
CN111093696B (en) * 2017-07-17 2023-10-27 詹森生物科技公司 Antigen binding regions of anti-type III fibronectin domains and methods of use thereof
US20190184028A1 (en) * 2017-12-14 2019-06-20 Janssen Biotech, Inc. Targeting with firbronectin type iii like domain molecules
BR112021022828A2 (en) * 2019-05-14 2022-04-12 Janssen Biotech Inc Combination therapies with bispecific anti-egfr/c-met antibodies and third-generation egfr tyrosine kinase inhibitors
KR20220063185A (en) 2019-09-16 2022-05-17 리제너론 파마슈티칼스 인코포레이티드 Radiolabeled MET binding protein for immuno-PET imaging
US11781138B2 (en) 2019-10-14 2023-10-10 Aro Biotherapeutics Company FN3 domain-siRNA conjugates and uses thereof
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
WO2022164284A1 (en) 2021-01-29 2022-08-04 주식회사 엘지화학 Electrode
WO2024002235A1 (en) * 2022-06-29 2024-01-04 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-egfr/met antibodies and uses thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE168416T1 (en) 1989-10-05 1998-08-15 Optein Inc CELL-FREE SYNTHESIS AND ISOLATION OF GENES AND POLYPEPTIDES
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (en) 1991-12-02 2008-12-22 Medical Res Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
AU5670194A (en) 1992-11-20 1994-06-22 Enzon, Inc. Linker for linked fusion polypeptides
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DK0985039T3 (en) 1997-06-12 2008-06-09 Novartis Int Pharm Ltd Artificial antibody polypeptides
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
US20130226834A1 (en) 2000-04-27 2013-08-29 Networth Services, Inc. Systems and methods for determining the financial status of bonds
MXPA03011365A (en) * 2001-06-13 2005-03-07 Genmab As Human monoclonal antibodies to epidermal growth factor receptor (egfr).
US7595378B2 (en) * 2001-06-13 2009-09-29 Genmab A/S Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
JP4602614B2 (en) 2001-09-26 2010-12-22 アイシン精機株式会社 Automotive door
WO2003037365A1 (en) 2001-11-01 2003-05-08 The Johns Hopkins University Methods and compositions for treating vascular leak using hepatocyte growth factor
KR101051245B1 (en) 2002-09-06 2011-07-21 이소제니카 리미티드 In Vitro Peptide Expression Libraries
US7407660B2 (en) 2003-04-16 2008-08-05 Genentech, Inc. Methods and compositions for selective modulation of vascularization
NZ544797A (en) * 2003-07-18 2011-04-29 Amgen Fremont Inc Specific antibodies that bind HGF and neutralise binding of HGF to met
JP2008504809A (en) 2004-06-04 2008-02-21 ジェネンテック・インコーポレーテッド EGFR mutation
CN101636410A (en) * 2006-11-22 2010-01-27 雅达思 The proteinic target therapeutic agent of through engineering approaches based on tyrosine kinase receptor (comprising IGF-IR)
WO2008127710A2 (en) * 2007-04-13 2008-10-23 Dana Farber Cancer Institute Methods for treating cancer resistant to erbb therapeutics
US20090042906A1 (en) 2007-04-26 2009-02-12 Massachusetts Institute Of Technology Methods for treating cancers associated with constitutive egfr signaling
EP2215115A1 (en) * 2007-11-08 2010-08-11 The University of Chicago Molecular affinity clamp technology and uses thereof
EP2231870A4 (en) 2007-12-19 2011-01-26 Centocor Ortho Biotech Inc Engineered phage vectors for the design and the generation of a human non-antibody peptide or protein phage library via fusion to pix of m13 phage
JP2011507519A (en) 2007-12-19 2011-03-10 セントコア・オーソ・バイオテツク・インコーポレーテツド Design and generation of human de novo pIX phage display library via fusion to pIX or pVII, vectors, antibodies, and methods
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
CN102014913A (en) 2008-03-06 2011-04-13 健泰科生物技术公司 Combination therapy with C-MET and EGFR antagonists
PE20091827A1 (en) 2008-04-11 2009-11-20 Galaxy Biotech Llc COMBINATION OF INHIBITOR HGF AND INHIBITOR EGF FOR THE TREATMENT OF CANCER
BRPI0913007A2 (en) * 2008-05-02 2019-09-24 Novartis Ag enhanced fibronectin-based binding molecules and uses thereof
EP2291399B1 (en) 2008-05-22 2014-06-25 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
US20110229469A1 (en) 2008-10-01 2011-09-22 Ludwig Institute For Cancer Research Methods for the treatment of cancer
PL2356269T3 (en) 2008-10-31 2016-12-30 Fibronectin type iii domain based scaffold compositions, methods and uses
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
US8545839B2 (en) * 2008-12-02 2013-10-01 Pierre Fabre Medicament Anti-c-Met antibody
DK2396011T3 (en) * 2009-02-12 2016-04-25 Janssen Biotech Inc Fibronectin TYPE III DOMAIN-BASED SCAFFOLD COMPOSITIONS, METHODS AND USES
KR20110126748A (en) 2009-04-07 2011-11-23 로슈 글리카트 아게 Bispecific anti-erbb-1/anti-c-met antibodies
EP3511342B1 (en) 2010-03-10 2024-01-17 Genmab A/S Monoclonal antibodies against c-met
JP2013523179A (en) * 2010-04-13 2013-06-17 メディミューン，エルエルシー Multimeric scaffolds based on fibronectin type III domains
US9150663B2 (en) 2010-04-20 2015-10-06 Genmab A/S Heterodimeric antibody Fc-containing proteins and methods for production thereof
TWI586806B (en) * 2010-04-23 2017-06-11 建南德克公司 Production of heteromultimeric proteins
EP3569256B1 (en) * 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
WO2012042026A1 (en) * 2010-09-30 2012-04-05 Ablynx Nv Biological materials related to c-met
BR112014007469B1 (en) 2011-09-27 2022-06-14 Janssen Biotech, Inc MANUFACTURING METHOD OF A LIBRARY OF TYPE III FIBRONECTIN MODULE DOMAINS (FN3), LIBRARY AND METHOD TO OBTAIN A PROTEIN FRAMEWORK
PT2855509T (en) 2012-05-25 2018-08-03 Janssen Biotech Inc Non-natural consensus albumin binding domains
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
SI2922872T1 (en) * 2012-11-21 2019-01-31 Janssen Biotech, Inc., Bispecific egfr/c-met antibodies
CN105899226B (en) * 2013-10-14 2020-05-12 詹森生物科技公司 Cysteine engineered fibronectin type III domain binding molecules

Also Published As

Publication number Publication date
CN108546300B (en) 2022-03-15
CN107098975A (en) 2017-08-29
CN104955473A (en) 2015-09-30
MX2019013117A (en) 2019-12-16
EA201590998A1 (en) 2016-02-29
NZ708349A (en) 2020-10-30
EA035559B1 (en) 2020-07-07
KR102210196B1 (en) 2021-02-01
IL238730B (en) 2019-12-31
JP6393270B2 (en) 2018-09-19
SG10201707488TA (en) 2017-10-30
WO2014081944A3 (en) 2014-07-17
JP7015223B2 (en) 2022-02-02
KR20150087340A (en) 2015-07-29
US9725497B2 (en) 2017-08-08
IL270852A (en) 2020-01-30
EP2922566A2 (en) 2015-09-30
US20210206825A1 (en) 2021-07-08
CN106977606B (en) 2021-08-27
ES2696148T3 (en) 2019-01-14
AU2020267284A1 (en) 2020-12-10
KR20210013324A (en) 2021-02-03
US20140155325A1 (en) 2014-06-05
IL238730A0 (en) 2015-06-30
UA118096C2 (en) 2018-11-26
AU2013347952A1 (en) 2015-05-28
MX2015006386A (en) 2015-12-03
AU2018241106B2 (en) 2020-08-20
EP2922566B1 (en) 2018-10-03
AU2013347952B2 (en) 2018-07-12
JP2019033748A (en) 2019-03-07
US20140155326A1 (en) 2014-06-05
US20170305997A1 (en) 2017-10-26
EP2922566A4 (en) 2016-10-26
NZ748444A (en) 2020-10-30
JP2022008534A (en) 2022-01-13
EP3485901B1 (en) 2021-10-13
IL270852B (en) 2020-09-30
US9695228B2 (en) 2017-07-04
CA2891485A1 (en) 2014-05-30
NI201500070A (en) 2015-09-21
AU2018241106A1 (en) 2018-10-25
ES2899292T3 (en) 2022-03-10
CL2015001353A1 (en) 2015-10-02
CN107098975B (en) 2021-11-05
CN106977606A (en) 2017-07-25
MX369334B (en) 2019-11-05
EP4023670A1 (en) 2022-07-06
US10954284B2 (en) 2021-03-23
EA036054B1 (en) 2020-09-21
AU2020267284B2 (en) 2022-03-31
PH12015501134B1 (en) 2015-08-17
CN108546300A (en) 2018-09-18
CN104955473B (en) 2018-05-18
PH12015501134A1 (en) 2015-08-17
EP3485901A1 (en) 2019-05-22
ZA201504427B (en) 2017-11-29
JP2016504291A (en) 2016-02-12
MY176820A (en) 2020-08-21
WO2014081944A9 (en) 2015-09-17
EA201791577A1 (en) 2017-11-30
CN113667020A (en) 2021-11-19
HK1215680A1 (en) 2016-09-09
WO2014081944A2 (en) 2014-05-30

Similar Documents

Publication Publication Date Title
IL270852B (en) Egfr and c-met-fibronectin type iii domain binding molecules
IL268336B (en) Il-18 binding molecules
ZA201406671B (en) Multispecific antigen-binding molecules and uses thereof
IL234234B (en) Ang2-binding molecules
HK1202556A1 (en) Single domain binding molecule
ZA201506186B (en) Ligand binding molecules and uses thereof
GB201219487D0 (en) Anti-S100A4 antibody molecules and their uses
EP2844267A4 (en) Broad spectrum erbb ligand binding molecules and methods for their use